Insmed Incorporated
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell INSM and other ETFs, options, and stocks.About INSM
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.
CEOWilliam H. Lewis
CEOWilliam H. Lewis
Employees1,271
Employees1,271
HeadquartersBridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded1988
Founded1988
Employees1,271
Employees1,271
INSM Key Statistics
Market cap30.85B
Market cap30.85B
Price-Earnings ratio-25.59
Price-Earnings ratio-25.59
Dividend yield—
Dividend yield—
Average volume2.22M
Average volume2.22M
High today$148.22
High today$148.22
Low today$144.00
Low today$144.00
Open price$145.91
Open price$145.91
Volume1.93M
Volume1.93M
52 Week high$149.08
52 Week high$149.08
52 Week low$60.40
52 Week low$60.40
INSM News
TipRanks 3d
Promising Market Potential for Insmed’s Brensocatib Drives Buy RatingInsmed, the Healthcare sector company, was revisited by a Wall Street analyst on September 8. Analyst Joseph Schwartz from Leerink Partners reiterated a Buy rat...
TipRanks 6d
Insmed price target raised to $172 from $125 at GuggenheimGuggenheim raised the firm’s price target on Insmed (INSM) to $172 from $125 and keeps a Buy rating on the shares as a result of updates that include increasing...
Analyst ratings
95%
of 20 ratingsBuy
95%
Hold
5%
Sell
0%
People also own
Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.